Aligos says Phase 1 follow-up data for pevifoscorvir sodium suggest reduction in HBV cccDNA reservoir

Aligos

Aligos

ALGS

0.00
  • Aligos flagged positive Phase 1 follow-up results for pevifoscorvir sodium in chronic hepatitis B, already presented at the EASL Congress 2026.
  • Post-treatment follow-up suggested antiviral effects persisted beyond dosing, supporting the drug’s strategy to shrink the viral reservoir.
  • Separate data indicated a meaningful share of treated patients could become eligible for add-on functional-cure regimens that include antisense therapy.
  • Preclinical combination work showed additive-to-synergistic activity for pevifoscorvir sodium with the ALG-170675 antisense program, supporting a multi-drug regimen approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270230PRIMZONEFULLFEED9726664) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.